**Core tip:** We have examined the relationship between changes in dairy intake, lipid species and vascular function. Although it was expected that an increase in dairy intake would lower blood pressure and be associated with improvements in vascular structure we found that increases in lipid species associated with dairy (LPC 14:0, LPC 15:0, LPC 16:1, CE 14:0) were associated with adverse changes in these parameters. Dairy does not appear to be beneficial in people with diabetes.

INTRODUCTION
============

By 2030 it is projected that 7.7% of the world's population will have diabetes, which is an increase of 54% since 2010\[[@B1]\]. Individuals with type 1 and type 2 diabetes are two-to-three times more likely to develop cardiovascular disease (CVD) compared with the general population\[[@B2]-[@B4]\]. In Australia, in 2010 approximately 30% of all deaths in people with type 1 and type 2 diabetes were due to CVD\[[@B5]\]. Poor diet is the leading contributor to the global burden of disease\[[@B6]\] and better dietary quality is associated with lower rates of CVD\[[@B7],[@B8]\]. The most recent evidence from prospective cohort studies suggests that dairy consumption is protective against CVD\[[@B9]\]. Although uncertainty remains about the vascular effects of dairy fatty acids\[[@B10]\].

Arterial stiffness measured by augmentation index and carotid femoral pulse wave velocity (cfPWV) are independent predictors of CVD\[[@B11],[@B12]\]. Similarly, carotid intima media thickness (IMT) is an early measure of atherosclerosis that predicts CVD\[[@B13],[@B14]\]. Epidemiological studies have indicated that higher consumption of dairy products is associated with lower carotid IMT\[[@B15],[@B16]\] and less arterial stiffening\[[@B15],[@B17]-[@B19]\].

Self-reported dietary intake is limited by inaccurate reporting, which is well-documented in the general population and people with diabetes\[[@B20]\]. Biomarkers of dietary intake, including dairy consumption, remove the reliance on self-reported dietary data. Previously it has been shown that fatty acids of ruminant origin are correlated with self-reported dietary intake of dairy products\[[@B19],[@B21]\].

The aim is to determine serum lipid species that change in response to a change in dairy consumption. Based on our previous analysis\[[@B19]\] we hypothesise that the following lipid species will reflect a change in dairy consumption: Cholesterol ester (CE) 14:0, CE 15:0, lysophosphatidylcholine (LPC) 14:0, LPC 15:0, LPC 17:1, phosphatidylcholine (PC) 29:0, PC 30:0, PC 31:0, PC 31:1, PC 33:0, PC 33:1, PC 33:3, PC 35:0, sphingomyelin (SM) 31:1, SM 32:0, triacylglycerol (TG) 16:0/16:0/16:0. The secondary aims are to determine the correlation between the change in dairy associated lipid species and 3-mo change in peripheral and central blood pressure, augmentation index and cfPWV. The 12-mo change in common carotid artery intima media thickness (CCA-IMT) will also be correlated with the change in lipid species.

MATERIALS AND METHODS
=====================

Study design
------------

As previously reported, a 12-mo randomised controlled trial was conducted to determine the effect of improving dietary quality on CCA-IMT, compared to a control group continuing on their habitual diet, in a cohort of people with type 1 and type 2 diabetes\[[@B22]\]. Briefly, participants were randomised to increase consumption of fruit (+1 serve/day), vegetables (+2 serves/day) and dairy (+1 serve/day), regardless of usual intake or to continue on their usual diet. One serve of dairy was either 250 mL of milk or 200 g of yoghurt and no advice was given regarding the fat content. Dietary counselling was provided by a dietitian. Ethics approval was obtained from the University of South Australian Human Research Ethics Committee and the participants provided written informed consent. The trial was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12613000251729) on 04/09/2014.

A post hoc analysis was conducted that comprised a subsample of the cohort (*n* = 108) that had serum lipidomic analysis performed at baseline and 3-mo. A food frequency questionnaire (FFQ) was used to measure dietary intake at baseline and 3-mo and a fasting serum sample was collected for measurement of lipid species. Participants had peripheral and central blood pressure, augmentation index and cfPWV measured at baseline and 3-mo. In addition, CCA-IMT was measured at baseline and 12-mo. The intervention to increase dairy by one serve per day was only partially successful with 34 people in the intervention group increasing and 17 decreasing their dairy consumption, while in the control group 23 increased and 34 reduced their dairy intake. Thus overall 57 people increased and 51 decreased dairy intake so the analyses were performed without regard for allocation to intervention or control.

Subjects
--------

Subjects above 18 years of age with diagnosed type 1 or type 2 diabetes for any duration managed with diet, oral hypoglycaemic agents (OHA) and/or insulin were recruited from August 2012 until December 2013 from a database of volunteers, public advertisements and a recruitment company (Intuito Market Research, Adelaide, South Australia). Exclusion criteria were: Unstable CVD requiring active intervention, heart failure, significant renal impairment (eGFR \< 30 mL/min), liver disease, cancer or allergic/intolerant/dislike of fruit, vegetables or dairy.

Serum lipid analysis
--------------------

Lipid analysis was performed on fasting serum by liquid chromatography, electrospray ionization-tandem mass spectrometry as previously published\[[@B23]\]. In total, 342 individual lipid species were measured from 23 classes.

Food frequency questionnaire
----------------------------

Habitual dietary intake was measured using the electronic version of the Dietary Questionnaire for Epidemiological Studies Version 2 FFQ. The FFQ includes questions on the types of milk (fat content), cheese (hard, firm, soft, ricotta, cottage cheese, cream cheese or low fat cheese) and spreads (butter) used. Questions about the quantity of milk consumed per day (none, \< 250 mL, 250-500 mL, 500-750 mL, \> 750 mL) and the frequency of cheese, yoghurt and ice-cream consumption are also included. This FFQ has been found to have relatively good agreement with a 3-d weighed food record in the general population\[[@B24]\] and in people with type 1 and type 2 diabetes\[[@B25]\].

Measurements
------------

Anthropometric measurements: Height was measured using a stadiometer (SECA, Hamburg, Germany) to the nearest 0.1 cm while barefoot/flat footwear. Weight was measured to the nearest 0.05 kg using calibrated electronic scales (SECA, Hamburg, Germany) while the participants were barefoot/light footwear and wore light clothing.

**Peripheral blood pressure:** Clinic blood pressure was measured using an automated sphygmomanometer (SureSigns VS3; Philips, North Ryde, Sydney, Australia) once the participant had been seated for 5 min. A normal sleeve (16 cm × 52 cm) was used for an arm circumference of 24-32 cm and a large sleeve (16 cm × 70 cm) for an arm circumference of 32-42 cm. A minimum of four consecutive readings were taken at 1 min intervals. The first reading was discarded and the following three consistent measurements, *i.e*., systolic blood pressure within a range of 1.3 kPa, were used.

**Common carotid artery intima media thickness:** The measurements of the carotid artery were taken using B mode ultra-sound by one operator, with an intra-observer coefficient of variation (CV) of 4.4% (*n* = 34). The participants were supine with their head positioned at 45 degrees away from the side of the neck being measured. A high resolution ultrasound machine with a 12 MHz transducer was used (Samsung Medison MySono U6, South Korea). A 1 cm region of the IMT on the far wall of the distal common carotid artery on both sides was measured using automatic edge detection software (Samsung Medison MySono U6 Auto IMT, South Korea) as recommended in the Mannheim Carotid Intima- Media Thickness Consensus Paper (2004-2006-2011)\[[@B26]\]. Areas of plaque, defined as a 50% greater IMT than the surrounding IMT or IMT \> 1.5 mm, were not imaged. Three seconds clips were captured and the mean of 10 measurements taken from each of these clips was averaged for a mean and mean maximum CCA-IMT value at baseline and 12 mo.

**Central blood pressure and augmentation index:** A SphygmoCor^®^ XCEL (AtCor Medical, West Ryde, Sydney, Australia) was used to measure central blood pressure and augmentation index. A cuff was placed over the brachial artery on the right arm and measurements were completed after the participants had been quietly resting for 5 min. Three consecutive measurements were taken and the average calculated. All of the measurements were taken by one operator with a CV of 4.2% (*n* = 28).

**Pulse wave velocity:** A SphygmoCor^®^ XCEL (AtCor Medical, West Ryde, Sydney, Australia) was used to measure cfPWV. The tonometer was placed on the right carotid artery and the cuff on the right femoral artery. A 10-s recording of the carotid-femoral waveform was taken. Three measurements were performed at each time-point and an average taken. The measurements were taken by two operators; the intra-observer CVs were 4.2% (*n* = 28) and 7.3% (*n* = 11), respectively and the inter-observer CV was 5.0% (*n* = 18).

Statistical analysis
--------------------

Data are presented as mean ± SD. The change in dairy intake between baseline and 3-mo was not different between the groups so the cohort was analysed as a whole. Paired samples *t*-tests were used to determine the change in dairy intake, anthropometric measures, blood pressure, biochemistry and vascular measurements over time.

Change in lipid species containing fatty acids 15:0, 16:1 and 17:0 known to be of ruminant origin\[[@B27]-[@B29]\] (CE 15:0, CE 16:1, CE 17:0, diacylglycerol (DG) 16:1/18:1, LPC 15:0, LPC 16:1, LPC 17:0, TG 15:0/18:1/16:0, TG 15:0/18:1/18:1, TG 16:1/16:1/16:1, TG 16:1/16:1/18:0, TG 16:1/16:1/18:1, TG 16:1/18:1/18:1, TG 16:1/18:1/18:2, TG 17:0/16:0/16:1, TG 17:0/16:0/18:0, TG 17:0/18:1/14:0, TG 17:0/18:1/16:0, TG 17:0/18:1/16:1, TG 17:0/18:1/18:1, TG 17:0/18:2/16:0) and those we have previously shown to be correlated with dairy consumption\[[@B19]\] (CE 14:0, CE 15:0, LPC 14:0, LPC 15:0, LPC 17:1, PC 29:0, PC 30:0, PC 31:0, PC 31:1, PC 33:0, PC 33:1, PC 33:3, PC 35:0, SM 31:1, SM 32:0, TG 16:0/16:0/16:0) were correlated with the 3-mo change in full fat dairy consumption. Spearman's correlation was used to correlate the change in dairy consumption with the change in lipid species because the data did not have a normal distribution. Lipid species that were correlated with the change in full fat dairy consumption were correlated with the change in vascular measurements. Both absolute and percent change (change/baseline × 100) are presented. No adjustment for multiple testing were made with this analysis. Secondary analyses involving all of the lipid species (\> 300) were conducted. Spearman's correlation was used to determine the association between the change in lipid species and the change in vascular measures. In addition, baseline concentrations of the lipid species were correlated with the change in vascular measures. These secondary analyses were corrected for multiple comparisons using the Benjamini Hochberg approach\[[@B30]\]. Analyses were performed using SPSS (version 19, 2010, SPSS Inc, Chicago, IL, United States). Statistical significance was set at *P* \< 0.05. The statistical methods of this study were reviewed by Ms Kylie Lange from the University of Adelaide, Australia.

RESULTS
=======

A total of 108 participants were involved in these analyses (Figure [1](#F1){ref-type="fig"}). Baseline characteristics of the participants included in this subsample were not different from non-participants with regards to age, weight, BMI, peripheral blood pressure, central systolic blood pressure, mean or mean maximum CCA-IMT. Central diastolic blood pressure, augmentation index, cfPWV and HbA1c were higher (*P* \< 0.05) in the non-participants compared with the participants. Baseline characteristics of the participants are presented in Table [1](#T1){ref-type="table"}.

###### 

Baseline characteristics of the participants *n* (%)

  **Characteristic**                                             **Cohort (*n* = 108)**
  -------------------------------------------------------------- ------------------------
  Age (yr)                                                       58 ± 14
  Weight (kg)                                                    96.2 ± 20.6
  BMI (kg/m^2^)                                                  32.6 ± 6.4
  Sex                                                            
  Female                                                         40 (37)
  Male                                                           68 (63)
  Diabetes type                                                  
  Type 1                                                         14 (13)
  Type 2                                                         94 (87)
  Time since diabetes diagnosis (yr)                             
  Type 1                                                         21 ± 13
  Type 2                                                         8 ± 7
  Smoking status                                                 
  Never smoked                                                   56 (52)
  Past smoker                                                    47 (43)
  Current smoker                                                 5 (5)
  Smoking pack years (years)[a](#T1FN1){ref-type="table-fn"}     10.5 ± 16.3
  Prescribed anti-hypertensive medication                        66 (61)
  Prescribed lipid lowering medication                           61 (57)
  Diabetes treatment                                             
  None                                                           22 (20)
  OHA                                                            49 (46)
  Insulin                                                        16 (15)
  OHA + insulin                                                  21 (19)
  Presence of Microalbuminuria[1](#T1FN2){ref-type="table-fn"}   14 (13)
  HbA1c                                                          7.1 ± 1.2

All values are mean ± SD or *n* (%) where specified;

Smoking pack years = number packs (25 cigarettes)/day × number years smoked;

Albumin:creatinine \> 2.5 for men and \> 3.5 for women. BMI: Body mass index; OHA: Oral hypoglycaemic agents.

![CONSORT diagram.](WJD-8-202-g001){#F1}

Table [2](#T2){ref-type="table"} shows consumption of dairy products measured using the FFQ. There was no significant change in total or full fat dairy consumption over time. Yoghurt consumption increased while cheese and butter consumption decreased. There was no effect of the treatment on dairy consumption or lipid levels, so we were able to examine the association between the change in dairy intake and the change in lipid species in the entire cohort to identify dairy associated lipid species. And we further analysed the correlation between the change in dairy associated lipid species and vascular measurements.

###### 

Dietary intake measured using a food frequency questionnaire

  **Intake (g/d)**                                       **Cohort (*n* = 108)**   ***P* value for change**   
  ------------------------------------------------------ ------------------------ -------------------------- -------
  Total dairy[1](#T2FN1){ref-type="table-fn"}            432 ± 218                434 ± 198                  0.90
  Total full fat dairy[1](#T2FN1){ref-type="table-fn"}   113 ± 201                94 ± 162                   0.16
  Milk                                                   349 ± 201                345 ± 188                  0.78
  Yoghurt                                                55 ± 65                  68 ± 76                    0.031
  Cheese                                                 14 ± 12                  11 ± 10                    0.005
  Butter                                                 2 ± 6                    1 ± 4                      0.051
  Ice-cream                                              11 ± 18                  9 ± 10                     0.063

Includes milk, yoghurt, cheese, butter, ice-cream. All values are mean ± SD; Data analysed using paired samples *t*-test.

Table [3](#T3){ref-type="table"} shows the results of correlating the change in lipid species containing 15:0, 16:1 or 17:0 or those identified as correlating with dairy intake in the previous cross-sectional study with the change in full fat dairy consumption (milk, yoghurt, cheese, butter and ice-cream). No adjustments were made.

###### 

Spearman's correlation of the change in total full fat dairy (milk, yoghurt, cheese, butter, ice-cream) with change in lipid species

  **Change in lipid species**   **rho value**   ***P* value**
  ----------------------------- --------------- ---------------
  LPC 14:0                      0.25            0.01
  LPC 15:0                      0.21            0.03
  LPC 16:1                      0.22            0.02
  PC 29:0                       0.22            0.02
  PC 30:0                       0.23            0.02
  PC 31:0                       0.19            0.049
  CE 14:0                       0.24            0.01

LPC: Lysophosphatidylcholine; PC: Phosphatidylcholine; CE: Cholesterol ester.

Table [4](#T4){ref-type="table"} shows the anthropometric measurements, blood pressure, biochemistry and vascular measurements at baseline and follow-up in the whole group. Measurements of central blood pressure and augmentation index were performed on 82 participants due to equipment availability. cfPWV was performed on 70 participants due to technical difficulties because of obesity. The lipid species that were shown to be correlated with total full fat dairy consumption (LPC 14:0, LPC 15:0, LPC 16:1, PC 29:0, PC 30:0, PC 31:0, CE 14:0) were then correlated with the vascular measurements that changed over time.

###### 

Anthropometric measures, blood pressure, biochemistry and vascular measurements at baseline and follow-up

                                               **Baseline**   **3 mo**                                      ***P* value for change**
  -------------------------------------------- -------------- --------------------------------------------- --------------------------
  Weight (kg)                                  96.2 ± 20.6    95.9 ± 20.6                                   0.40
  Peripheral systolic blood pressure (kPa)     16.9 ± 2.0     16.9 ± 1.9                                    0.75
  Peripheral diastolic blood pressure (kPa)    9.4 ± 1.3      9.4 ± 1.3                                     0.69
  Peripheral mean arterial pressure (kPa)      12 ± 1.3       12 ± 1.3                                      0.69
  Peripheral pulse pressure (kPa)              7.4 ± 1.3      7.4 ± 1.7                                     0.93
  Central systolic blood pressure (kPa)        16.8 ± 1.3     16.1 ± 1.9                                    0.004
  Central diastolic blood pressure (kPa)       10.9 ± 1.3     10.5 ± 1.2                                    0.002
  Central mean arterial pressure (kPa)         13.2 ± 1.5     12.8 ± 1.3                                    0.002
  Central pulse pressure (kPa)                 5.9 ± 1.7      5.8 ± 1.7                                     0.09
  Central augmented pressure (kPa)             1.2 ± 0.6      1.1 ± 0.8                                     0.07
  Augmentation index (%)                       19 ± 7         21 ± 12                                       0.005
  cfPWV (m/s)                                  9.4 ± 1.7      9.4 ± 1.8                                     0.63
  Pulse transit time (m/s)                     60 ± 10        60 ± 9                                        0.95
  CCA-IMT (mm)                                 0.72 ± 0.12    0.71 ± 0.12[1](#T4FN1){ref-type="table-fn"}   0.002
  Total cholesterol (mmol/L)                   3.7 ± 1.0      3.7 ± 1.0                                     0.59
  HDL cholesterol (mmol/L)                     1.2 ± 0.3      1.2 ± 0.3                                     0.54
  LDL cholesterol (mmol/L)                     2.0 ± 0.8      2.0 ± 0.7                                     0.40
  Triglycerides (mmol/L)                       1.1 ± 0.9      1.1 ± 0.9                                     0.53
  Glucose (mmol/L)                             7.3 ± 2.9      7.3 ± 2.7                                     0.95
  High sensitivity C reactive protein (mg/L)   2.5 ± 2.4      2.4 ± 2.4                                     0.80

Follow-up was at 12 mo. All values are mean ± SD. Data analysed using paired samples *t*-test. cfPWV: Carotid femoral pulse wave velocity; CCA-IMT: Common carotid artery intima media thickness; HDL: High density lipoprotein; LDL: Low Density lipoprotein.

Table [5](#T5){ref-type="table"} presents the results of these analyses including both absolute and percent change in each parameter. Percent and absolute change in LPC 14:0, PC 30:0 and PC 31:0 were correlated with percent and absolute change in central systolic and diastolic blood pressure and central mean arterial pressure. Change in central diastolic blood pressure was correlated with the change in LPC 15:0, LPC 16:1, PC 29:0 and PC 31:0. Change in central mean arterial pressure was also correlated with the change in PC 31:0. The absolute and percent change in CCA-IMT was correlated with the absolute and percent change in CE 14:0 only. There were no lipid species that were associated with the change in augmentation index or cfPWV. Change in full fat dairy consumption itself was not associated with the change in any of the vascular measurements. When the change in all of the lipid species (*n* \> 300) was examined after correction for multiple comparisons, there were no significant correlations between any of the lipid species and the change in central systolic and diastolic blood pressure, central mean arterial pressure, augmentation index or CCA-IMT.

###### 

Spearman's correlation between the absolute and percent change in dairy associated lipid species and the absolute and percent change in vascular measures

                                     **Absolute change**   **Percent change**          
  ---------------------------------- --------------------- -------------------- ------ -------
  Central systolic blood pressure                                                      
  LPC 14:0                           0.30                  0.007                0.28   0.01
  PC 30:0                            0.28                  0.010                0.31   0.004
  PC 31:0                            0.20                  0.07                 0.22   0.046
  Central diastolic blood pressure                                                     
  LPC 14:0                           0.32                  0.004                0.32   0.00
  LPC 15:0                           0.23                  0.04                 0.22   0.046
  LPC 16:1                           0.23                  0.035                0.21   0.06
  PC 29:0                            0.28                  0.01                 0.34   0.002
  PC 30:0                            0.36                  0.001                0.40   0.001
  PC 31:0                            0.30                  0.007                0.31   0.004
  Central mean arterial pressure                                                       
  LPC 14:0                           0.30                  0.007                0.29   0.009
  PC 29:0                            0.21                  0.06                 0.25   0.025
  PC 30:0                            0.31                  0.005                0.33   0.002
  PC 31:0                            0.24                  0.033                0.24   0.028
  Augmentation index                                                                   
  Nil significant                                                                      
  cfPWV                                                                                
  Nil significant                                                                      
  CCA-IMT                                                                              
  CE 14:0                            0.22                  0.02                 0.23   0.02

LPC: Lysophosphatidylcholine; PC: Phosphatidylcholine; CE: Cholesterol ester; cfPWV: Carotid femoral pulse wave velocity; CCA-IMT: Common carotid artery intima media thickness.

Baseline concentration of PC 34:4 (rho = -0.32; *P* \< 0.0001), PC 32:2 (rho = -0.33; *P* \< 0.0001), G~M3~ ganglioside (GM3) 16:0 (rho = -0.34; *P* \< 0.0001), GM3 18:0 (rho = -0.38; *P* = 0.0001) and total GM3 (rho = -0.36; *P* = 0.0003) were inversely associated with the change in CCA-IMT, after adjustment for multiple comparisons. The change in central systolic and diastolic blood pressure, central mean arterial pressure, augmentation index or cfPWV were not associated with the concentration of any lipid species at baseline after correction for multiple comparisons.

DISCUSSION
==========

These analyses show that a change in the concentration of a number of serum lipid species (LPC 14:0, LPC 15:0, LPC 16:1, PC 29:0 PC 30:0, PC 31:0, CE 14:0), previously shown to be correlated with dairy consumption, were associated with a change in full fat dairy consumption in the present study. One or more of these lipid species were positively associated with the 3-mo change in central blood pressure and 12-mo change in CCA-IMT in this cohort with type 1 and type 2 diabetes.

Fatty acids C 15:0 and C 17:0 are not produced endogenously and are constituents of dairy fat. The fatty acid C 14:0 is produced endogenously but is also a component of dairy fat. Therefore these fatty acids in plasma or for C 14:0 in adipose tissue are considered biomarkers of dairy intake\[[@B28]\]. In the present study change in LPC 15:0, LPC 14:0 and CE 14:0 were weakly positively correlated with the change in consumption of full fat dairy. LPC concentration in milk fat is \< 1% of the total PC concentration and therefore dairy would be an unlikely direct source of LPC species\[[@B21]\]. LPC lipid species are predominately produced endogenously through a number of different processes including from PC by phospholipase A~2~ enzyme and the oxidation of LDL particles\[[@B31],[@B32]\].

In a randomised cross-over study, consumption of a full fat dairy diet containing non-fermented products (butter, cream or ice cream) was associated with higher plasma concentrations of sphingomyelin compared with low-fat dairy intake\[[@B33]\]. Plasma concentrations of odd chain phosphatidylcholine (15:0 and 17:0) were increased with consumption of both full fat fermented (including yoghurt and cheese) and non-fermented dairy products. In this study vascular measurements were not performed. Previously we showed a cross-sectional association between serum lipid species and consumption of full fat dairy in people with type 1 and type 2 diabetes but serum lipid species were not associated with arterial stiffness despite dairy consumption being inversely associated with cfPWV\[[@B19]\]. In addition, baseline CCA-IMT was not associated with any serum lipid species. In the present study, changes in serum lipid species were associated with the change in central blood pressure (LPC 14:0, LPC 15:0, LPC 16:1, PC 29:0, PC 30:0, PC 31:0) and the change in CCA-IMT (CE 14:0). In addition, baseline concentration of PC 34:4, PC 32:2, GM3 16:0, GM3 18:0 and total GM3 were associated with the change in CCA-IMT such that higher baseline levels were associated with greater CCA-IMT regression. GM3 accumulation has been observed in intimal atherosclerotic lesions in the carotid artery and aorta\[[@B34]\] and serum GM3 has been identified as a potential marker of early atherosclerosis\[[@B35]\]. Therefore this finding suggests that those with greater atherosclerotic burden at baseline had greater CCA-IMT regression which is consistent with our previous finding\[[@B22]\].

This study shows that when dairy associated serum lipids species were reduced at 3-mo there was a reduction in central blood pressure and CCA-IMT. Conversely when there was an increase in these serum lipid species central blood pressure increased. This finding is not consistent with previous research showing an inverse association between dairy consumption and blood pressure\[[@B17],[@B36]\]. Machin et al\[[@B36]\] showed that consuming a high dairy diet (non-fat) for 4 wk reduced central blood pressure and cfPWV compared with a high fruit diet. The relationship we observed whereby an increase in LPC 14:0, LPC 15:0 and LPC 16:1 was associated with an increase in central blood pressure may be explained by the proinflammatory and atherogenic properties of non-omega 3 polyunsaturated fatty acid enriched LPC\[[@B37]\]. LPCs act on endothelial cells, smooth muscle cells, monocytes, macrophages and T-cells in a number of ways to inhibit endothelial relaxation and up-regulate production of inflammatory and adhesion molecules\[[@B32],[@B38]\]. Inflammation, measured by CRP, has been positively associated with blood pressure and development of hypertension\[[@B39],[@B40]\], which may explain our findings in the current study. As such, our results may not be due to the fatty acid composition *per se* but fatty acid metabolism and resulting lipid species. Previously total phospholipid C 15:0 has been inversely associated with blood pressure and coronary heart disease\[[@B41]\]. Although it remains unclear what the mechanism behind this finding is and this should be explored in the future.

Ruminant fatty acids C 15:0 and C 17:0 do not have the same physiological effects as other saturated fatty acids (although they have not been tested in isolation) and are not associated with increased risk of cardiovascular outcomes and may actually be protective\[[@B42],[@B43]\]. Dairy products also contain many other components such calcium, magnesium, phosphorus, potassium and bioactive peptides that may contribute to the cardio-protective effect of dairy consumption\[[@B44]-[@B46]\]. In a four-way cross-over study it was shown that the calcium content of dairy products counteracts the fat content to attenuate the increase in total and LDL cholesterol, without reducing HDL cholesterol\[[@B44]\]. The synergist effect of the different components in dairy products may explain why dairy consumption was not associated with any of the vascular measurements in the current study despite the observed association between the lipid species and these measurements.

Nestel et al\[[@B21]\] showed that the phospholipid classes LPC and lysoalkylphosphatidylcholine were associated with measures of insulin sensitivity and insulin resistance. In addition, full fat dairy consumption was associated with phospholipid fatty acids C 15:0, C 16:1 and C 18:1 n-7 but there was no relationship detected between dairy consumption and insulin sensitivity or resistance measures. This is similar to the findings of the present study whereby the change in dairy consumption was not associated with the change in central blood pressure or CCA-IMT, but the change in a number of lipid species was associated with both the change in dairy intake and the change in central blood pressure and CCA-IMT. This may be because lipid analysis provides a more objective measure of intake and is not limited by the measurement error associated with self-reported dietary intake, although it may be due to a lack of statistical power.

Limitations of this study are that it is observational and therefore causation cannot be established. In addition, just over half of the cohort were prescribed lipid lowering medication which may confound the results. Finally, this study comprises a small sample size and findings should be replicated in a larger cohort. We also did not have lipidomic data at 12-mo but we assumed changes early in the observation period would be required in order see changes in IMT at 12-mo.

In conclusion, in this cohort with type 1 and type 2 diabetes a number of serum lipid species that were associated with a change in full fat dairy consumption were also correlated with the 3-mo change in central blood pressure and 12-mo change in CCA-IMT.
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